Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies

Reuters02-11
Tempest <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies

Tempest Therapeutics Inc. has announced a strategic plan to advance its newly acquired CAR-T and oncology assets using a capital-efficient approach. The company will prioritize development of its dual-targeting CD19/BCMA CAR-T therapy, TPST-2003, with ongoing and future clinical trials in China funded by a strategic partner. Tempest also plans to expand its portfolio with TPST-4003, an in vivo CAR-T program, which will undergo preclinical development and potential partner-funded clinical evaluation. Additionally, Tempest aims to position its Phase 3-ready amezalpat program for pivotal development through business development partnerships. The company intends to initiate a Phase 2 study of TPST-1495 in familial adenomatous polyposis, funded by the National Cancer Institute. Overall, Tempest’s strategy centers on leveraging external funding to generate clinical data while advancing a diversified next-generation CAR-T pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652581-en) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment